SynBiotic Shares Rebound Even as Insolvency Filing Remains Unconfirmed
Published on 10/27/2026 at 19:21 | Editorial boerse-global.de
Shares in SynBiotic climbed sharply on Thursday, yet the advance says nothing about the status of the company's insolvency proceedings. A check of the official insolvency portal turned up no court ruling on the matter through October 21, according to a media report — and the register gives no indication whether the application has even been filed.
The gain, put at 8.2% in one account and 15% in another, reflects nothing more than market movement. SynBiotic itself has warned that neither the outcome of any proceedings nor their economic impact on shareholders can be reliably estimated.
Filing Announced, Not Confirmed
On October 16, the company said it intended to apply to the district court in Münster (Amtsgericht Münster) to open insolvency proceedings over its own assets. That announcement described the step as planned; the register entry, as of the October 21 cutoff, does not establish that the application has actually been submitted. A search of the official portal covering October 7 to 21 returned no entries for the company.
Cannabis Market and Financing Behind the Move
SynBiotic pointed to a persistently difficult market environment in the cannabis sector as one reason for the announcement. The conditions had weighed on both business performance and the company's financial position.
Should investors sell immediately? Or is it worth buying SynBiotic?
Two further factors compounded the strain. The company said it could not secure the necessary financing in time, and it also lacked shareholder approval at the annual general meeting to create new capital. Market conditions, funding and the missing authorization for capital measures were all cited by SynBiotic as grounds for its decision.
Operations to Continue for Now
Under the October 16 statement, a preliminary insolvency administrator was to be appointed, and SynBiotic planned to keep operating initially. That commitment carried an explicit time qualifier: business was to continue at first, not as an unconditional promise for what follows.
For shareholders, the company attached a clear caveat. Neither the course of the proceedings nor their economic consequences for equity holders could be reliably assessed, it said — meaning the announcement came with no dependable estimate of what lies ahead for investors.
SynBiotic at a turning point? This analysis reveals what investors need to know now.
mwb research Pulls Its Rating
mwb research placed both its rating and its price target for SynBiotic "UNDER REVIEW" on October 19, responding to the announced insolvency filing. The research house had previously carried a speculative "Spec. BUY" recommendation with a price target of EUR 1.40. In suspending coverage, mwb research put that assessment under review without naming a new, specific target.
Ad
SynBiotic Stock: New Analysis - 27 October
Fresh SynBiotic information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
